Telix Pharmaceuticals Ltd. (TLX) Securities Class Action Lawsuit Filed [November 14, 2025]

Introduction to Telix Pharmaceuticals Ltd. (TLX) Securities Class Action Lawsuit

A securities fraud class action has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) in the U.S. District Court for the Southern District of Indiana. The case covers investors who acquired Telix securities between February 21, 2025 and August 28, 2025, inclusive. Investors allege the company overstated progress on its prostate cancer therapeutic candidates and exaggerated the strength of its manufacturing and supply chain. The truth surfaced when Telix disclosed an SEC subpoena focused on its prostate therapeutic disclosures and later announced an FDA Complete Response Letter citing manufacturing and partner deficiencies. Following these events, Telix's ADSs fell sharply across multiple trading days, inflicting significant losses on shareholders.

Telix Pharmaceuticals Ltd. (TLX) Securities Lawsuit Case Details

Case Name: Thomas v. Telix Pharmaceuticals Ltd., et al.
Case No.: 1:25-cv-02299
Jurisdiction: U.S. District Court, Southern District of Indiana
Filed on: November 10, 2025

Telix Pharmaceuticals Ltd. (TLX) Company Profile

Telix is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Its American Depositary Shares trade on the Nasdaq Global Select Market under the ticker symbol TLX.

Telix Pharmaceuticals Ltd. (TLX) Securities Lawsuit Class Period

February 21, 2025–August 28, 2025, inclusive.

All persons or entities who purchased or otherwise acquired publicly traded Telix securities during the Class Period may be eligible to join the Telix Pharmaceuticals Ltd. (TLX) class action lawsuit.

Allegations in the Telix Pharmaceuticals Ltd. (TLX) Securities Class Action Lawsuit

Investors sued Telix Pharmaceuticals Ltd., CEO Christian P. Behrenbruch, CFO Darren Smith, and Senior Vice President Kyahn Williamson, alleging they misled the market about pipeline progress and supply chain readiness. The complaint centers on statements about Telix's prostate cancer therapeutic candidates and the company's manufacturing and distribution capabilities.

On February 20, 2025, Williamson told investors on a 2024 earnings call that Telix was "making great progress across our therapeutic pipeline," highlighting late-stage assets including the prostate cancer program "now in Phase 3." That same day, Behrenbruch emphasized that Telix had been building and scaling the infrastructure needed to deliver products globally "with a high degree of confidence for patients." Months later, during the August 20, 2025 1H 2025 earnings call, CFO Darren Smith said Telix was investing strategically in manufacturing and supply chain infrastructure to preserve a competitive edge and scale with demand, while Behrenbruch stressed the importance of a "robust, reliable supply chain" for long-term success.

According to the complaint, these assurances were misleading because Defendants materially overstated the progress of the prostate cancer therapeutic candidates and the quality of Telix's supply chain and partners. As alleged, statements about the company's business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times.

The Truth Emerges

The disclosure sequence began on July 22, 2025, when Telix filed a Form 6-K announcing it had received an SEC subpoena seeking documents and information "primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates." According to the complaint, the SEC subpoena related to disclosures the company had made about the development of its prostate cancer therapeutic candidates. 

Then, on August 28, 2025, Telix announced it received an FDA Complete Response Letter identifying deficiencies in the Chemistry, Manufacturing, and Controls package. The company stated the FDA requested additional data to establish comparability between the drug used in the ZIRCON Phase 3 trial and the scaled-up commercial process, and documented Form 483 notices to two third-party manufacturing and supply chain partners requiring remediation before resubmission. According to the complaint, these revelations contradicted prior statements about the company's supply chain, which the complaint alleges materially overstated its quality.

Market Reaction

After the July 22, 2025 subpoena disclosure, Telix ADSs fell $1.70, or 10.4%, to close at $14.58 on July 23, 2025, and declined another $0.69, or 4.7%, to close at $13.89 on July 24, 2025.

Following the August 28, 2025 FDA letter, the ADSs dropped $1.95, or 16.1%, to close at $10.15 on August 28, 2025, and fell a further $0.60, or 5.9%, to close at $9.55 on August 29, 2025.

Next Steps

• Submissions for lead plaintiff are due January 9, 2026.
• The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
• The Court will then consider motion for class certification.
• The Court will later consider a Motion to Dismiss.

To learn if you are eligible for recovery under the TLX securities class action lawsuit, visit the case submission page here.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.